Therapeutic effect of sorafenib is attenuated by tumor-infiltrating Ly6G+myeloid-derived suppressor cells (MDSCs) and is restored by anti-interleukin-6 (IL-6) antibody treatment in an orthotopic mouse liver cancer model

臺大醫院-小兒部;臺大醫院-腫瘤醫學部;臺大醫院-醫學研究部;臺大醫學院-免疫學研究所;臺大醫學院-腫瘤醫學研究所;臺大醫學院-醫學檢驗暨生物技術學系暨研究所;Chang, Chun-JungChun-JungChangYang, Yao-HsuYao-HsuYangChiu, Chiao-JunoChiao-JunoChiuChiang, Bor-LuenBor-LuenChiangLee, Xiao-yiXiao-yiLeeHsu, Chih-HungChih-HungHsuCheng, Ann-LiiAnn-LiiCheng鄭安理2017-05-252018-07-092017-05-252018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/278961[SDGs]SDG3Therapeutic effect of sorafenib is attenuated by tumor-infiltrating Ly6G+myeloid-derived suppressor cells (MDSCs) and is restored by anti-interleukin-6 (IL-6) antibody treatment in an orthotopic mouse liver cancer model10.1158/1538-7445.AM2015-461